SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 19.02 |
| Enterprise Value ($M) | 9.77 |
| Book Value ($M) | -2.90 |
| Book Value / Share | -0.18 |
| Price / Book | -6.56 |
| NCAV ($M) | -4.00 |
| NCAV / Share | -0.25 |
| Price / NCAV | -4.76 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -1.30 |
| Return on Equity (ROE) | -1.97 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.78 |
| Current Ratio | 0.78 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 11.89 |
| Assets | 12.99 |
| Liabilities | 15.89 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -52.36 |
| Net Income | -51.21 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -44.59 |
| Cash from Investing | 9.96 |
| Cash from Financing | 6.91 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Nantahala Capital Management, LLC | 1.50 | -98.02 | |
| 13D/A | Hanmi Pharmaceutical Co., Ltd. | 22.17 | 238.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,895 | 33,688 | 14.53 | |
| 10,106 | 37,493 | 26.95 | |
| 12,615 | 17,427 | 72.39 | |
| 10,259 | 9,589 | 106.99 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ANIX – Anixa Biosciences, Inc. | APM – Aptorum Group Limited |
| APRE – Aprea Therapeutics, Inc. | APVO – Aptevo Therapeutics Inc. |
| ARTL – Artelo Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io